Excavated with colonial labor and shipped to the Netherlands, the famous fossil is being repatriated to Indonesia along with 28,000 other fossils. The skull cap of 'Java Man' was discovered by Eugène ...

TL;DR: DRAM contract prices surged 171.8% year-over-year in Q3 2025, driven by high demand from AI, cloud, and data centers amid supply shortages. DDR5 memory costs have doubled, with Korean ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. It continues with an explanation on obfuscation within the Java Edition: "For a long time, Java ...

New Analyze Applications feature analyzes JAR or WAR files for migrations and JFR recordings for performance optimization. Update also brings task scheduling and Kubernetes support. Oracle Java ...

Memory loss is one of the most unsettling experiences a person can face. While it’s often linked to conditions such as dementia or Alzheimer’s disease, even minor lapses can feel alarming. Forgetting ...

While you may have been distracted by Apple’s new product releases and interesting operating system enhancements, the company also quietly a powerful new security feature this week: Memory Integrity ...

What if the very tool you rely on for precision and productivity started tripping over its own memory? Imagine working on a critical project, only to find that your AI assistant, Claude Code, is ...

Firms that perform audits, reviews, or compilations have a little more than four months to implement the new risk-based quality management (QM) standards. The task may feel daunting, but Joe Lynch, ...

A new survey reveals that nearly 80% of ITAM and SAM professionals are moving away from Oracle Java, citing cost hikes, audit risks, and licensing confusion as key drivers. Nearly 8 in 10 ...

Want smarter insights in your inbox? Sign up for our weekly newsletters to get only what matters to enterprise AI, data, and security leaders. Subscribe Now A team of researchers from leading ...

Both Vertex and Eli Lilly are entering the non-opioid pain management market, targeting the promising $20B+ opportunity. Vertex's Journavx, targeting NaV1.8, is FDA-approved and shows opioid-level ...